• Aliases: PEG-IFN alfa-2b; pegylated interferon alfa-2b; SCH54301
    • A covalent conjugate of recombinant interferon alpha, subtype 2b, and PEG that bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects
    • FDA approved for melanoma adjuvant treatment with microscopic or gross nodal involvement within 84 days of definitive surgical resection, including complete lymphadenectomy
    • Recommended dose: 6 mg/kg/week SubQ for 8 doses, then maintenance dose with 3 μg/kg/week for up to 5 years. May need premedication with acetaminophen 650 mg PO thereafter
    Other topics in Targeted and Immunotherapy Agents